Comparative Pharmacology
Head-to-head clinical analysis: E E S versus ERYTHROMYCIN ESTOLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E E S versus ERYTHROMYCIN ESTOLATE.
E.E.S. vs ERYTHROMYCIN ESTOLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin (E.E.S.) binds to the 50S subunit of bacterial ribosomes, inhibiting peptide chain elongation and protein synthesis. It also exhibits prokinetic effects on the gastrointestinal tract via motilin receptor agonism.
Erythromycin estolate is a macrolide antibiotic that reversibly binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step. It may also exhibit immunomodulatory and anti-inflammatory effects.
250-500 mg every 6 hours orally or 15-20 mg/kg/day IV divided every 6 hours.
250-500 mg orally every 6-12 hours
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolonged to 4-6 hours in patients with hepatic impairment; may be shorter in children.
Approximately 1.5-2 hours in normal adults; prolonged to 5-6 hours in end-stage renal disease.
Primarily hepatic (biliary) excretion of unchanged drug and active metabolites; approximately 15% of an oral dose is excreted unchanged in urine. The remainder is eliminated via feces as unchanged drug and metabolites.
Primarily hepatic via biliary excretion into feces; approximately 2-5% excreted unchanged in urine. <5% renal elimination.
Category C
Category A/B
Macrolide Antibiotic
Macrolide Antibiotic